Trial Profile
Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 24 Sep 2019 Primary endpoint (Change from baseline in insulin dose) has been met published in the Clinical Drug Investigation
- 24 Sep 2019 Results assessing the extent to which ipragliflozin add-on therapy can reduce the insulin dose in Japanese type 2 diabetes mellitus patients treated with basal insulin published in the Clinical Drug Investigation
- 22 Nov 2017 Status changed from active, no longer recruiting to completed.